Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Epilepsy × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 60 Glioma 23 Brain Neoplasms 23 Gliosarcoma 21 Melanoma 15 Central Nervous System Neoplasms 12 Astrocytoma 10 Neuroblastoma 9 Rhabdomyosarcoma 6 Neoplasms 6 Neoplasm Metastasis 6 Medulloblastoma 6 Sarcoma, Ewing 5 Recurrence 5 Small Cell Lung Carcinoma 4 Ovarian Neoplasms 4 Osteosarcoma 4 Oligodendroglioma 4 Wilms Tumor 3 Sarcoma 3 Neuroectodermal Tumors, Primitive, Peripheral 3 Ependymoma 3 Diffuse Intrinsic Pontine Glioma 3 Breast Neoplasms 3 Rhabdoid Tumor 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Optic Nerve Glioma 2 Lymphoma 2 Kidney Neoplasms 2

Interventions

Temozolomide 1 Sulfasalazine 1 Sirolimus 1 Radiotherapy 1 Memantine 1 Gabapentin 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05664464 2024-05-10

GLUGLIO

University of Zurich

Phase 1/2 Recruiting

Epilepsy, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡